Closing Soon
Prevention as prevention of bronchiectasis in cystic fibrosis, sponsored by Telethon Institute for Child Health Research
Get in touch This trial recruits from January 2012 for 132 weeks
Dr Catherine Gangell
Phone: +61 7 3636 4074
Fax: +61 7 3636 5578
Email: c.gangell@uq.edu.au
Address:
Queensland Children's Medical Research Institute
University of Queensland
Level 4, Foundation Building
Royal Children's Hospital
Herston Rd
Herston, Qld 4029
Inclusion Criteria
Age: From 6 weeks To 6 months
Gender: Both males and females
- Children of either sex with a diagnosis of CF following detection via New Born Screening (NBS);
- Participants who, in the opinion of the Investigator, are able to comply with the protocol for its duration;
- Written informed consent signed and dated by parent/legal guardian according to local regulations
Exclusion Criteria
- Born <30 weeks gestation;
- Prolonged mechanical ventilation in the first 3 months of life;
- Participation in another randomized controlled trial within the 3 months preceding inclusion in this study;
- A significant medical disease or condition other than CF that is likely to interfere with the childs ability to complete the entire protocol;
- Previous major surgery except for meconium ileus;
- Macrolide hypersensitivity
ACTRNACTRN12610001072000
A Phase 3 multi-centre randomised placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis
Prevention of bronchiectasis in infants with cystic fibrosis